

New treatment for HCM
CAMZYOS® (mavacamten) - The first and to date only cardiac myosin inhibitor for the treatment of adults with symptomatic (New York Heart Association, NYHA, functional class II-III) obstructive hypertrophic cardiomyopathy (oHCM).1
A treatment that increases physical performance and reduces symptom burden (p<0.0005).*1